journal article·2023-05Open access

Nanovaccines Displaying the Influenza Virus Hemagglutinin in an Inverted Orientation Elicit an Enhanced Stalk‐Directed Antibody Response

Steven J. Frey, Juan Manuel Carreño, Dominika Bielak, Ammar Arsiwala, Clara G. Altomare, Chad Varner, Tania Rosen‐Cheriyan, Goran Bajic, Florian Krammer, Ravi S. Kane

Advanced Healthcare Materials· Volume 12· Issue 13

Abstract

Abstract Despite the availability of licensed vaccines, influenza causes considerable morbidity and mortality worldwide. Current influenza vaccines elicit an immune response that primarily targets the head domain of the viral glycoprotein hemagglutinin (HA). Influenza viruses, however, readily evade this response by acquiring mutations in the head domain. While vaccines that target the more conserved HA stalk may circumvent this problem, low levels of antistalk antibodies are elicited by vaccination, possibly due to the poor accessibility of the stalk domain to B cell receptors. In this work, it is demonstrated that nanoparticles presenting HA in an inverted orientation generate tenfold higher antistalk antibody titers after a prime immunization and fivefold higher antistalk titers after a boost than nanoparticles displaying HA in its regular orientation. Moreover, nanoparticles presenting HA in an inverted orientation elicit a broader antistalk response that reduces mouse weight loss and improves survival after challenge to a greater extent than nanoparticles displaying HA in a regular orientation. Refocusing the antibody response toward conserved epitopes by controlling antigen orientation may enable the design of broadly protective nanovaccines targeting influenza viruses and other pathogens with pandemic potential.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Influenza Virus Research Studies · Respiratory viral infections research · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Chemical & Biomolecular Engineering Georgia Institute of Technology Atlanta GA 30332 USA

Department of Microbiology Icahn School of Medicine at Mount Sinai New York NY 10029 USA

Center for Vaccine Research and Pandemic Preparedness (C‐VaRPP) Icahn School of Medicine at Mount Sinai New York NY 10029 USA

Department of Pathology Molecular and Cell Based Medicine Icahn School of Medicine at Mount Sinai New York NY 10029 USA

Wallace H. Coulter Department of Biomedical Engineering Georgia Institute of Technology Atlanta GA 30332 USA

Funding

Simons Foundation

References (44)

Show source-provided references
1. 10.1038/nrd452910.1038/nrd4529 ↗
2. 10.1371/journal.pone.002579710.1371/journal.pone.0025797 ↗
3. 10.1038/nature0689010.1038/nature06890 ↗
4. 10.1128/JVI.03509-1210.1128/JVI.03509-12 ↗
5. 10.1038/ni.276110.1038/ni.2761 ↗
6. 10.1038/nm114110.1038/nm1141 ↗
7. 10.1353/bhm.2002.002210.1353/bhm.2002.0022 ↗
8. 10.1073/pnas.132052411010.1073/pnas.1320524110 ↗
9. 10.1128/mBio.03617-2010.1128/mBio.03617-20 ↗
10. 10.1038/s41598-018-28706-110.1038/s41598-018-28706-1 ↗
11. 10.1016/j.coviro.2012.02.00510.1016/j.coviro.2012.02.005 ↗
12. 10.1128/JVI.00469-1210.1128/JVI.00469-12 ↗
13. 10.1371/journal.ppat.100079610.1371/journal.ppat.1000796 ↗
14. 10.1126/science.117149110.1126/science.1171491 ↗
15. 10.1126/science.120483910.1126/science.1204839 ↗
16. 10.1128/JVI.00641-1310.1128/JVI.00641-13 ↗
17. 10.1371/journal.pone.000394210.1371/journal.pone.0003942 ↗
18. 10.1016/j.coviro.2016.02.00210.1016/j.coviro.2016.02.002 ↗
19. 10.1128/JVI.02608-1310.1128/JVI.02608-13 ↗
20. 10.1038/s41467-017-02725-410.1038/s41467-017-02725-4 ↗
21. 10.1126/science.aac726310.1126/science.aac7263 ↗
22. 10.1073/pnas.130870111010.1073/pnas.1308701110 ↗
23. 10.1073/pnas.140276611110.1073/pnas.1402766111 ↗
24. 10.1038/nm.392710.1038/nm.3927 ↗
25. 10.1016/S1473-3099(19)30393-710.1016/S1473-3099(19)30393-7 ↗
26. 10.3389/fimmu.2019.0075610.3389/fimmu.2019.00756 ↗
27. 10.1111/imr.1290010.1111/imr.12900 ↗
28. 10.1172/jci.insight.12903510.1172/jci.insight.129035 ↗
29. 10.1073/pnas.181630011610.1073/pnas.1816300116 ↗
30. 10.1126/scitranslmed.aad052210.1126/scitranslmed.aad0522 ↗
31. 10.1371/journal.ppat.100410310.1371/journal.ppat.1004103 ↗
32. 10.1016/j.vaccine.2014.07.07410.1016/j.vaccine.2014.07.074 ↗
33. 10.1002/adhm.20200214010.1002/adhm.202002140 ↗
34. 10.1038/s42003-021-02128-810.1038/s42003-021-02128-8 ↗
35. 10.1016/j.coviro.2016.03.00110.1016/j.coviro.2016.03.001 ↗
36. 10.1038/371623a010.1038/371623a0 ↗
37. 10.1038/s41598-021-98706-110.1038/s41598-021-98706-1 ↗
38. 10.1016/j.jmb.2008.04.04910.1016/j.jmb.2008.04.049 ↗
39. 10.1186/1477-3155-9-2210.1186/1477-3155-9-22 ↗
40. 10.1038/ni.368010.1038/ni.3680 ↗
41. 10.1038/s41423-022-00897-810.1038/s41423-022-00897-8 ↗
42. Margine I. · J. Vis. Exp. · 2013 · 81
43. 10.1016/j.jmb.2013.09.01610.1016/j.jmb.2013.09.016 ↗
44. 10.1038/nprot.2008.2010.1038/nprot.2008.20 ↗